Scottish consensus statement on the role of FeNO in adult asthma

Chris Ruiwen Kuo; Mark Spears; John Haughney; Andrew Smith; Joy Miller; Tracey Bradshaw; Lorna Murray; Peter Williamson; Brian Lipworth

doi:10.1016/j.rmed.2019.07.010

Scottish consensus statement on the role of FeNO in adult asthma

Chris Ruiwen Kuo, Mark Spears, John Haughney, Andrew Smith, Joy Miller, Tracey Bradshaw, Lorna Murray, Peter Williamson, Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journal › Review article › peer-review

35 Citations (Scopus)

236 Downloads (Pure)

Abstract

Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.

Original language	English
Pages (from-to)	54-57
Number of pages	4
Journal	Respiratory Medicine
Volume	155
Early online date	6 Jul 2019
DOIs	https://doi.org/10.1016/j.rmed.2019.07.010
Publication status	Published - Aug 2019

Keywords

Asthma
FeNO
Type 2 Inflammation

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.rmed.2019.07.010

Author Accepted ManuscriptAccepted author manuscript, 488 KBLicence: CC BY-NC-ND

Cite this

@article{0151b594fa724f65b0e0b537c151e234,

title = "Scottish consensus statement on the role of FeNO in adult asthma",

abstract = "Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.",

keywords = "Asthma, FeNO, Type 2 Inflammation",

author = "Kuo, {Chris Ruiwen} and Mark Spears and John Haughney and Andrew Smith and Joy Miller and Tracey Bradshaw and Lorna Murray and Peter Williamson and Brian Lipworth",

year = "2019",

month = aug,

doi = "10.1016/j.rmed.2019.07.010",

language = "English",

volume = "155",

pages = "54--57",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Scottish consensus statement on the role of FeNO in adult asthma

AU - Kuo, Chris Ruiwen

AU - Spears, Mark

AU - Haughney, John

AU - Smith, Andrew

AU - Miller, Joy

AU - Bradshaw, Tracey

AU - Murray, Lorna

AU - Williamson, Peter

AU - Lipworth, Brian

PY - 2019/8

Y1 - 2019/8

N2 - Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.

AB - Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.

KW - Asthma

KW - FeNO

KW - Type 2 Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85068553685&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2019.07.010

DO - 10.1016/j.rmed.2019.07.010

M3 - Review article

C2 - 31299469

SN - 0954-6111

VL - 155

SP - 54

EP - 57

JO - Respiratory Medicine

JF - Respiratory Medicine

ER -

Scottish consensus statement on the role of FeNO in adult asthma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this